People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

A new study published in the Journal of Medical Internet Research has found that regular participation in dance classes can ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Ozzy Osbourne has been battling a rare form of Parkinson's Disease known as Parkin 2. In 2020, he disclosed to his fans that ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...